Biofrontera, Inc.
(NASDAQ : BFRI)

( )
BFRI PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.62%51.400.9%$2116.73m
JNJJohnson & Johnson 0.62%164.370.7%$1382.14m
MRKMerck & Co., Inc. 1.25%73.180.7%$1043.36m
BMYBristol-Myers Squibb Co. 0.81%57.591.0%$831.23m
LLYEli Lilly & Co. -0.35%244.251.1%$718.99m
ABBVAbbVie, Inc. 0.31%121.891.9%$627.54m
AZNAstraZeneca Plc 0.68%55.131.0%$309.49m
NVSNovartis AG 0.83%81.350.2%$178.86m
GSKGlaxoSmithKline Plc 0.70%42.680.2%$161.90m
DRNADicerna Pharmaceuticals, Inc. -0.42%38.000.3%$157.34m
VTRSViatris, Inc. 0.24%12.430.0%$141.06m
BFRIBiofrontera, Inc. 12.13%4.900.0%$131.89m
RPRXRoyalty Pharma Plc 1.58%39.160.1%$121.97m
RGENRepligen Corp. 2.85%266.036.7%$99.58m
NVONovo Nordisk A/S 2.96%113.420.1%$88.62m

Company Profile

Biofrontera, Inc. is a biopharmaceutical company which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, in particular, diseases caused primarily by exposure to sunlight that result in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs; and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.